Choose a country

Spain Flag Australia
Brazil Flag Brazil
Canada Flag Canada
Colombia Flag Colombia
Germany Flag Germany
Netherlands Flag Netherlands
Portugal Flag Portugal
Spain Flag Spain
Germany Flag Sweden
United Kingdom Flag United Kingdom
United States Flag United States
To see the other countries, please click here.
Choose another country or region to see content specific to your location. Thank you!
Patients & Caregivers Healthcare Providers

The Right Dose at The Right Time

Aligning clinical practice to increase chances to achieve a therapeutic response in your patients

View the brochure

Approximately 50% of VNS Therapy™ patients take longer than 1 year to reach target dosing1

How does the VNS Therapy™ System improve outcomes for patients with DRE?

Although VNS Therapy has effectively helped manage Drug-Resistant Epilepsy (DRE) for more than 25 years, post-marketing surveillance of dosing practice revealed that approximately 50% of VNS Therapy patients take longer than 1 year to reach target dosing. Yet achieving a therapeutic response is key to improving patient outcomes.1,2

Compare your dosing practice to the latest data

Key Dosing Parameters

Together, output current, pulse width, and signal frequency can be considered the dose of VNS Therapy. Duty cycle can be regarded as dosing frequency.

key parameters

 

Output current and pulse width comprises the target volume whereas signal frequency and duty cycle can be considered as the therapeutic neural modulation ‘message’ for VNS Therapy. 

Patients implanted and dosed shortly after their initial DRE diagnosis were shown to benefit from VNS Therapy. However, chronically underdosed patients currently on VNS Therapy may still benefit from target-range titration.2

Key considerations during dosing to improve patient outcomes*

Target

Reach the target range for dosing

Consider the target dose combination for DRE patients as3:

Target-dosing-(2).PNG

VNS titration

Use rapid titration

Patients who were titrated to target within 3 months according to the recommended protocol achieve onset of response faster.1,3

Side effects for VNS Therapy™ in DRE patients may be similar regardless of the speed of titration schedule.1 Adjust settings as needed to ensure tolerability as patients habituate to stimulation.

How does your VNS TherapyTM dosing practice compare?

Take part in our short quiz to find out how your practice compares to the most recent data behind VNS Therapy dosing.

Compare your dosing practice to the latest data

Achieving a therapeutic response is key to improve patient outcomes. Explore a range of resources to support you in the dosing prcoess.

The Right Dose at The Right Time

Dosing brochure

The Right Dose at The Right Time

View Brochure
Fahoum clinical summary paper image

VNS Therapy™ Parameters for Clinical Response

View Clinical Summary
Clinical summary image Tzadok

Rapid Titration Reduces Time-To-Response

View Clinical Summary
SenTiva Dosing Guidelines

Dosing Guidelines - SenTiva™, SenTiva™ Duo

Download Dosing Guidelines
AspireSR, Demipulse, Demipulse Duo Dosing Guidelines Thumbnail

Dosing Guidelines - Other Models

Download Dosing Guidelines

For further dosing support, get in touch or contact your local VNS Therapy™ representative.

Contact Us
VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time

Safety Profile

VNS Therapy™ has no drug interactions and does not cause drug-related toxic central nervous system side effects.

Common side effects include hoarseness or change in voice tone, shortness of breath, sore throat, and coughing. Most side effects associated with VNS Therapy occur only during stimulation, tend to diminish over time, or are eliminated by adjusting parameter settings.

The most common side effect of the surgical procedure is infection.

For more safety information click here.

This information is not intended to serve as a substitute for a complete and thorough understanding of the material presented in the Physician’s Manuals for the VNS Therapy system and its component parts and does not represent full disclosure of all pertinent information concerning the use of this product, potential safety complications, or efficacy outcomes.

References

1. Tzadok, M., Verner, R., Kann, L., Tungala, D., Gordon, C., El Tahry, R., & Fahoum, F. (2022). Rapid Titration of VNS Therapy Reduces Time-To-Response in Epilepsy. Epilepsy and Behavior. 
2. Fahoum F, Boffini M, Kann L, et al. VNS parameters for clinical response in epilepsy. Brain Stimul. 2022;(15):814-821. 
3. VNS Therapy™ System Epilepsy Physician’s Manual (OUS), LivaNova USA, Inc. 
 

This website is intended for healthcare professionals in the United Kingdom. VNS Therapy™ for drug-resistant epilepsy is not available in all regions - please refer to your country-specific labeling.